HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Sandeep Tyagi Selected Research

moxifloxacin (Avelox)

9/2013Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.
7/2013Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
8/2009Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.
4/2008Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
12/2007In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
7/2006Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
12/2005Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
12/2005Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
11/2004Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.
2/2004Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD

Sandeep Tyagi Research Topics

Disease

23Tuberculosis (Tuberculoses)
09/2013 - 06/2002
7Infection
09/2013 - 06/2002
4Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)
09/2013 - 06/2005
2Granuloma
09/2013 - 07/2011
1Buruli Ulcer
01/2013
1Hypertension (High Blood Pressure)
07/2012
1Pain (Aches)
10/2011
1Inflammation
10/2011
1Lung Neoplasms (Lung Cancer)
10/2011
1Obesity
10/2011
1Neurodegenerative Diseases (Neurodegenerative Disease)
10/2011
1Dyslipidemias (Dyslipidemia)
10/2011
1Shock
12/2005
1Latent Tuberculosis
12/2005
1Necrosis
02/2005
1Hypersensitivity (Allergy)
03/2004
1Body Weight (Weight, Body)
06/2002

Drug/Important Bio-Agent (IBA)

11moxifloxacin (Avelox)FDA Link
09/2013 - 06/2002
11PyrazinamideFDA LinkGeneric
09/2013 - 02/2004
8Rifampin (Rifampicin)FDA LinkGeneric
01/2013 - 02/2004
8Isoniazid (Ftivazide)FDA LinkGeneric
09/2012 - 06/2002
5PA 824IBA
01/2011 - 06/2005
4rifapentine (Priftin)FDA Link
12/2007 - 12/2005
3Ethambutol (Myambutol)FDA LinkGeneric
09/2013 - 12/2005
2Amikacin (A.M.K)FDA LinkGeneric
09/2013 - 03/2013
2Drug CombinationsIBA
03/2013 - 10/2008
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
02/2005 - 03/2004
2Transcription Factors (Transcription Factor)IBA
04/2004 - 06/2002
1Verapamil (Calan)FDA LinkGeneric
09/2013
1Clofazimine (Lamprene)FDA Link
09/2013
1Ofloxacin (Levofloxacin)FDA LinkGeneric
07/2013
1mycolactoneIBA
01/2013
1Streptomycin (Streptomycin Sulfate)FDA Link
01/2013
1trichostatin A (A 300)IBA
11/2012
1atorvastatin (Lipitor)FDA Link
07/2012
1Losartan (Cozaar)FDA LinkGeneric
07/2012
1Phosphatidylinositols (Phosphatidylinositol)IBA
07/2012
1Acetylcholine (Acetylcholine Chloride)FDA Link
07/2012
1Desoxycorticosterone (DOCA)FDA Link
07/2012
1Glutathione (Reduced Glutathione)IBA
07/2012
12,4-thiazolidinedione (thiazolidinedione)IBA
07/2012
1Peroxisome Proliferator-Activated Receptors (PPAR)IBA
10/2011
1Anti-Bacterial Agents (Antibiotics)IBA
07/2011
1NitroimidazolesIBA
01/2011
1PNU-100480IBA
08/2009
1linezolid (Zyvox)FDA Link
08/2009
1rifamycin SVIBA
07/2006
1Ethionamide (Trecator-SC)FDA Link
12/2005
1DNA (Deoxyribonucleic Acid)IBA
12/2005
1Sigma FactorIBA
02/2005
1Tuberculin (PPD)IBA
03/2004
1ThioredoxinsIBA
06/2002
1Virulence Factors (Pathogenicity Factors)IBA
06/2002

Therapy/Procedure

4Drug Therapy (Chemotherapy)
09/2013 - 02/2004
1Aftercare (After-Treatment)
01/2013
1Subcutaneous Injections
07/2012
1Combination Drug Therapy (Combination Chemotherapy)
08/2006